Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Cipla acquires 30...

    Cipla acquires 30 percent stake in Brandmed for Rs 32 crore

    GarimaWritten by Garima Published On 2019-04-18T09:15:08+05:30  |  Updated On 16 Aug 2021 11:42 AM IST




    The acquisition of Brandmed is expected to complete by May 31. The transaction worth Rs 32 crore will be executed by the company's South African arm Cipla Medpro.

    Mumbai: Pharmaceutical major Cipla Ltd is acquiring 30 per cent stake in South African company Brandmed to increase its exposure to the connected healthcare segment.

    Besides the upfront cash payment, the transaction also involves milestone payments spread over three years on meeting profit targets. The transaction worth Rs 32 crore will be executed by the company's South African arm Cipla Medpro.

    Read Also: Cipla, Pulmatrix join hands to co-develop Pulmazole for treating asthma

    In February, Cipla had announced a similar partnership in India with Wellthy Therapeutics to offer a clinically-validated digital disease management platform to patients in cardio-metabolic health.

    The company said in a statement that it expects to complete the transaction with Brandmed by May 31.

    "This will help to transition healthcare from being reactive to a proactive and real-time monitoring model that focuses on promoting wellness instead of managing illness," said Paul Miller, Chief Executive Officer of Cipla Medpro.

    Read Also: Cipla launches respiratory inhalation therapy product Niveoli in India

    "By pairing our strengths with Brandmed' s innovative, patient-centric approach to healthcare, Cipla Medpro will enhance its diverse portfolio in the non-communicable disease area to provide holistic care to patients from awareness through to disease management, thereby enabling patient adherence and compliance."

    Founded in 2014, Brandmed has developed an integrated solution to address outcomes and value-based care for patients with chronic lifestyle and non-communicable diseases.

    Read Also: Cipla signs over Rs 152 crore pact with Pulmatrix for new asthma drug Pulmazole

    According to the World Health Organisation, more than 38 million people die annually from non-communicable diseases like cardiovascular ailments, cancers, chronic respiratory disorders and diabetes.



    Acquistionbrandmedcancerscardiovascular ailmentschronic lifestylechronic respiratory disordersCiplacipla acquistionCipla MedprodiabetesHealthcareholistic careIndiaMumbaiNon Communicable DiseasesSouth African BrandmedWellthy TherapeuticsWHOWorld Health Organisation
    Source : ANI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Garima
    Garima

      Garima joined Medical Dialogues in the year 2017 and is currently working as a Senior Editor. She looks after all the Healthcare news pertaining to Medico-legal cases, MCI/DCI decisions, Medical Education issues, government policies as well as all the news and updates concerning Medical and Dental Colleges in India. She is a graduate from Delhi University. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751 To know about our editorial team click here

      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok